[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  $gpcr $GPCR is attracting attention with positive sentiment, but investors are watching for the next move regarding safety and potential acquisition. The company's lead drug is under scrutiny, with the market focused on its safety profile and potential for big pharma acquisition. ### About $gpcr A pharmaceutical company focused on developing novel therapeutics, particularly in the area of GLP-1 receptor agonists for metabolic diseases. ### Engagements: XXXXX [#](/topic/$gpcr/interactions) ---  [Engagements 24-Hour Time-Series Raw Data](/topic/$gpcr/time-series/interactions.tsv) **Current Value**: XXXXX **Daily Average**: XXXXXX **1 Week**: XXXXXX -XX% **1 Month**: XXXXXXX -XX% **1-Year High**: XXXXXXX on 2025-06-25 **1-Year Low**: XX on 2025-09-14 | Social Network | X | | -------------- | - | | Engagements | XXXXX | ### Mentions: XX [#](/topic/$gpcr/posts_active) ---  [Mentions 24-Hour Time-Series Raw Data](/topic/$gpcr/time-series/posts_active.tsv) **Current Value**: XX **Daily Average**: XX **1-Year High**: XXX on 2025-08-22 **1-Year Low**: X on 2025-09-14 | Social Network | X | | -------------- | - | | Mentions | XX | ### Creators: XX [#](/topic/$gpcr/contributors_active) ---  [Creators 24-Hour Time-Series Raw Data](/topic/$gpcr/time-series/contributors_active.tsv) XX unique social accounts have posts mentioning $gpcr in the last XX hours which is up XX% from XX in the previous XX hours **Daily Average**: XX **1-Year High**: XXX on 2025-06-27 **1-Year Low**: X on 2025-09-14 The most influential creators that mention $gpcr in the last XX hours | Creator | Rank | Followers | Posts | Engagements | | ------- | ---- | --------- | ----- | ----------- | | [@bioinvestor24](/creator/twitter/bioinvestor24) | X | XXXXX | X | XXX | | [@BiopharmIQ](/creator/twitter/BiopharmIQ) | X | XXXXXX | X | XXX | | [@PersimmonTI](/creator/twitter/PersimmonTI) | X | XXXXXX | X | XX | | [@BowTiedBiotech](/creator/twitter/BowTiedBiotech) | X | XXXXXX | X | XX | [View More](/list/creators/$gpcr/100) ### Sentiment: XX% [#](/topic/$gpcr/sentiment) ---  [Sentiment 24-Hour Time-Series Raw Data](/topic/$gpcr/time-series/sentiment.tsv) **Current Value**: XX% **Daily Average**: XX% **1 Week**: XX% -XX% **1 Month**: XX% -XX% **1-Year High**: XXX% on 2025-05-13 **1-Year Low**: XX% on 2025-10-05 **Most Supportive Themes** - **GLP-1 Therapy Benefits:** (45%) Posts highlight the positive impacts of GLP-1 therapy, including weight loss and improved health markers. - **Positive Sentiment on $GPCR:** (25%) Several posts express optimism about $GPCR's potential, particularly regarding its CEO and market opportunity. - **Broader GLP-1 Market Discussion:** (15%) Discussions about the broader GLP-1 market, including comparisons with competitors and potential acquisitions. **Most Critical Themes** - **Safety Concerns and Side Effects:** (10%) Mentions of potential side effects and safety concerns associated with GLP-1 therapies. - **Comparison to Competitors:** (5%) Comparisons to competitors, with some questioning $GPCR's efficacy and potential for success. Network engagement breakdown: | Network | Positive | % | Neutral | % | Negative | % | | ------- | -------- | - | ------- | - | -------- | - | | X | XXX | XX% | XXX | XX% | X | X% | | | | | | | | | | Total | XXX | XX% | XXX | XX% | X | X% | **Top assets mentioned** In the posts about $gpcr in the last XX hours [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Metsera, Inc. Common Stock (MTSR)](/topic/$mtsr) [Dyne Therapeutics, Inc. Common Stock (DYN)](/topic/dyne-therapeutics) [Pfizer, Inc. (PFE)](/topic/$pfe) [Dyne Therapeutics, Inc. Common Stock (DYN)](/topic/$dyn) [Eli Lilly and Company (LLY)](/topic/eli-lilly) [Bitcoin Incognito (XBI)](/topic/$xbi) [Novo-Nordisk (NVO)](/topic/$nvo) [Hims & Hers Health, Inc. (HIMS)](/topic/hims-hers) [SuperRare (RARE)](/topic/superrare) **Top topics mentioned** In the posts about $gpcr in the last XX hours [stocks healthcare](/topic/stocks-healthcare), [$vktx](/topic/$vktx), [$mtsr](/topic/$mtsr), [dyne therapeutics](/topic/dyne-therapeutics), [$pfe](/topic/$pfe), [$dyn](/topic/$dyn), [eli lilly](/topic/eli-lilly), [$psnl](/topic/$psnl), [acquisition](/topic/acquisition), [$xbi](/topic/$xbi), [coins dao](/topic/coins-dao), [$nvo](/topic/$nvo), [hims hers](/topic/hims-hers), [superrare](/topic/superrare), [superrarebears](/topic/superrarebears), [coins solana ecosystem](/topic/coins-solana-ecosystem), [$cdtx](/topic/$cdtx), [$dhr](/topic/$dhr), [$wves](/topic/$wves), [gsk plc](/topic/gsk-plc), [$gsk](/topic/$gsk), [positions](/topic/positions), [$crvs](/topic/$crvs), [$lrmr](/topic/$lrmr), [$unh](/topic/$unh), [$lulu](/topic/$lulu), [$drug](/topic/$drug), [$ewtx](/topic/$ewtx), [$bbc](/topic/$bbc), [$janx](/topic/$janx), [$agio](/topic/$agio), [alt aptoslaunch token](/topic/alt-aptoslaunch-token), [$alt](/topic/$alt), [$alec](/topic/$alec), [$advm](/topic/$advm), [$rci](/topic/$rci), [$lbtya](/topic/$lbtya), [$blnd](/topic/$blnd), [stocks financial services](/topic/stocks-financial-services), [$200m2b](/topic/$200m2b), [stocks bitcoin treasuries](/topic/stocks-bitcoin-treasuries), [$bwb](/topic/$bwb), [$ante](/topic/$ante), [fold holdings](/topic/fold-holdings), [$crml](/topic/$crml), [$cenx](/topic/$cenx), [$ag](/topic/$ag), [brad](/topic/brad), [$uamy](/topic/$uamy), [$azn](/topic/$azn), [$vik](/topic/$vik), [$atxs](/topic/$atxs), [$elvn](/topic/$elvn), [investment](/topic/investment), [$tdoc](/topic/$tdoc), [$beam](/topic/$beam), [$mrk](/topic/$mrk), [$cytk](/topic/$cytk), [behind the](/topic/behind-the), [$akro](/topic/$akro) ### Top Social Posts [#](/topic/$gpcr/posts) --- Top posts by engagements in the last XX hours *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "Several other obesity catalysts remain for the year the could indirectly impact $VKTX $LLY $NVO. Biggest is Lilly Trump deal that could redefine the whole sector Lilly retatrutide phase X in OS. I doubt it will look as clean as from AEs some may expect . but will add OA as another GLP1 massive indication that Medicare cant ignore Several other phase X trials from $AZN $GPCR $NVO ( amycretin in T2D) Roche $TERN $AMGN and others. And obesity M&A news could emerge any day or not this year" [X Link](https://x.com/bioinvestor24/status/1977812550004953546) [@bioinvestor24](/creator/x/bioinvestor24) 2025-10-13T19:03Z 4381 followers, 5361 engagements "Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q4 2025 (3/3). $ALT Phase 2b $ALEC Phase X $ADVM Phase X $ZBIO Phase X $PCVX Phase X $RARE Phase X $TRAW Phase X $GPCR Phase 2b $SLS Phase X $RHHBY Phase X $MREO Phase X $KMDA Phase X $INSM Phase X $ATOS Phase X $ARTV Phase 2a $ALZN Phase X $AGIO Phase X $ADCT Phase X $TLPH Phase X $STOK Phase X $RLMD Phase X $REGN Phase 2/3 $PBYI Phase X $PBYI Phase X $NVS Phase X $NAMS Phase X $NAMS Phase X $NAMS Phase X $MRNA Phase X $INKT Phase X $LSTA Phase 2b $KZIA Phase X $JAZZ Phase X $IONS Phase X $INAB Phase X $IMMP Phase 2/3 $GNFT Phase X $FBIO" [X Link](https://x.com/BiopharmIQ/status/1977473383878230508) [@BiopharmIQ](/creator/x/BiopharmIQ) 2025-10-12T20:36Z 27.4K followers, XXX engagements "@2000STOCKMASTER I used to like $GPCR but Attain X screwed all small molecules. Orforglipron has the best PK and best early clinical data and still disappointed Structure drug has big derisking event soon that could killed it or make it" [X Link](https://x.com/bioinvestor24/status/1977163975533162891) [@bioinvestor24](/creator/x/bioinvestor24) 2025-10-12T00:06Z 4387 followers, XXX engagements "@bioinvestor24 sont forget $gpcr under thevradar and a major takeover candidate" [X Link](https://x.com/2000STOCKMASTER/status/1977155533111951491) [@2000STOCKMASTER](/creator/x/2000STOCKMASTER) 2025-10-11T23:33Z 1939 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$gpcr
$GPCR is attracting attention with positive sentiment, but investors are watching for the next move regarding safety and potential acquisition. The company's lead drug is under scrutiny, with the market focused on its safety profile and potential for big pharma acquisition.
About $gpcr
A pharmaceutical company focused on developing novel therapeutics, particularly in the area of GLP-1 receptor agonists for metabolic diseases.
Engagements: XXXXX #
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXXX
1 Week: XXXXXX -XX%
1 Month: XXXXXXX -XX%
1-Year High: XXXXXXX on 2025-06-25
1-Year Low: XX on 2025-09-14
| Social Network | X |
|---|---|
| Engagements | XXXXX |
Mentions: XX #
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
1-Year High: XXX on 2025-08-22
1-Year Low: X on 2025-09-14
| Social Network | X |
|---|---|
| Mentions | XX |
Creators: XX #
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning $gpcr in the last XX hours which is up XX% from XX in the previous XX hours
Daily Average: XX
1-Year High: XXX on 2025-06-27
1-Year Low: X on 2025-09-14
The most influential creators that mention $gpcr in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @bioinvestor24 | X | XXXXX | X | XXX |
| @BiopharmIQ | X | XXXXXX | X | XXX |
| @PersimmonTI | X | XXXXXX | X | XX |
| @BowTiedBiotech | X | XXXXXX | X | XX |
Sentiment: XX% #
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
1 Week: XX% -XX%
1 Month: XX% -XX%
1-Year High: XXX% on 2025-05-13
1-Year Low: XX% on 2025-10-05
Most Supportive Themes
- GLP-1 Therapy Benefits: (45%) Posts highlight the positive impacts of GLP-1 therapy, including weight loss and improved health markers.
- Positive Sentiment on $GPCR: (25%) Several posts express optimism about $GPCR's potential, particularly regarding its CEO and market opportunity.
- Broader GLP-1 Market Discussion: (15%) Discussions about the broader GLP-1 market, including comparisons with competitors and potential acquisitions.
Most Critical Themes
- Safety Concerns and Side Effects: (10%) Mentions of potential side effects and safety concerns associated with GLP-1 therapies.
- Comparison to Competitors: (5%) Comparisons to competitors, with some questioning $GPCR's efficacy and potential for success.
Network engagement breakdown:
| Network | Positive | % | Neutral | % | Negative | % |
|---|---|---|---|---|---|---|
| X | XXX | XX% | XXX | XX% | X | X% |
| Total | XXX | XX% | XXX | XX% | X | X% |
Top assets mentioned In the posts about $gpcr in the last XX hours
Viking Therapeutics, Inc (VKTX) Metsera, Inc. Common Stock (MTSR) Dyne Therapeutics, Inc. Common Stock (DYN) Pfizer, Inc. (PFE) Dyne Therapeutics, Inc. Common Stock (DYN) Eli Lilly and Company (LLY) Bitcoin Incognito (XBI) Novo-Nordisk (NVO) Hims & Hers Health, Inc. (HIMS) SuperRare (RARE)
Top topics mentioned In the posts about $gpcr in the last XX hours
stocks healthcare, $vktx, $mtsr, dyne therapeutics, $pfe, $dyn, eli lilly, $psnl, acquisition, $xbi, coins dao, $nvo, hims hers, superrare, superrarebears, coins solana ecosystem, $cdtx, $dhr, $wves, gsk plc, $gsk, positions, $crvs, $lrmr, $unh, $lulu, $drug, $ewtx, $bbc, $janx, $agio, alt aptoslaunch token, $alt, $alec, $advm, $rci, $lbtya, $blnd, stocks financial services, $200m2b, stocks bitcoin treasuries, $bwb, $ante, fold holdings, $crml, $cenx, $ag, brad, $uamy, $azn, $vik, $atxs, $elvn, investment, $tdoc, $beam, $mrk, $cytk, behind the, $akro
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Several other obesity catalysts remain for the year the could indirectly impact $VKTX $LLY $NVO. Biggest is Lilly Trump deal that could redefine the whole sector Lilly retatrutide phase X in OS. I doubt it will look as clean as from AEs some may expect . but will add OA as another GLP1 massive indication that Medicare cant ignore Several other phase X trials from $AZN $GPCR $NVO ( amycretin in T2D) Roche $TERN $AMGN and others. And obesity M&A news could emerge any day or not this year"
X Link @bioinvestor24 2025-10-13T19:03Z 4381 followers, 5361 engagements
"Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q4 2025 (3/3). $ALT Phase 2b $ALEC Phase X $ADVM Phase X $ZBIO Phase X $PCVX Phase X $RARE Phase X $TRAW Phase X $GPCR Phase 2b $SLS Phase X $RHHBY Phase X $MREO Phase X $KMDA Phase X $INSM Phase X $ATOS Phase X $ARTV Phase 2a $ALZN Phase X $AGIO Phase X $ADCT Phase X $TLPH Phase X $STOK Phase X $RLMD Phase X $REGN Phase 2/3 $PBYI Phase X $PBYI Phase X $NVS Phase X $NAMS Phase X $NAMS Phase X $NAMS Phase X $MRNA Phase X $INKT Phase X $LSTA Phase 2b $KZIA Phase X $JAZZ Phase X $IONS Phase X $INAB Phase X $IMMP Phase 2/3 $GNFT Phase X $FBIO"
X Link @BiopharmIQ 2025-10-12T20:36Z 27.4K followers, XXX engagements
"@2000STOCKMASTER I used to like $GPCR but Attain X screwed all small molecules. Orforglipron has the best PK and best early clinical data and still disappointed Structure drug has big derisking event soon that could killed it or make it"
X Link @bioinvestor24 2025-10-12T00:06Z 4387 followers, XXX engagements
"@bioinvestor24 sont forget $gpcr under thevradar and a major takeover candidate"
X Link @2000STOCKMASTER 2025-10-11T23:33Z 1939 followers, XXX engagements